Zealand Pharma to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology

Data ReadoutpositivepetrelintidePositive

AI Analysis

Summary

Zealand Pharma will present additional Phase 2 ZUPREME-1 trial data for petrelintide at EASD 2026 and announces publication of trial results in The Lancet Diabetes & Endocrinology.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Additional Phase 2 ZUPREME-1 trial data to be presented at EASD 2026; trial results published in The Lancet Diabetes & Endocrinology

Importance:6/10

Sentiment:

0.60

Phase 2 datapetrelintideZUPREME-1diabetespublicationEASD 2026

Related Companies

$ZEAL

Read the original article

Published by GlobeNewswire Pharma on September 29, 2026 10:03 PM

Read Original